Text Size
Santen Global

2015 Press Release

RSS

Press Release

NICE recommends the use of IKERVIS® in England for the treatment of severe keratitis in adult patients with dry eye disease
Santen Announces Financial Result for the Second Quarter ended September 30, 2015
Santen Reports Consolidated Performance For the First Half of FY2015
Notice on Details of Subscription Rights to New Shares (Stock Options for Stock-Linked Remuneration)
Santen Announces Approval of TAPROS for the Treatment of Open-Angle Glaucoma and Ocular Hypertension in China
Santen Announces Financial Result for the First Quarter ended June 30, 2015
Santen to Grant Subscription Rights to New Shares as Stock Options for Stock-Linked Remuneration
Notice of Completion of the Transfer of Anti-Rheumatic Pharmaceutical Business to AYUMI Pharmaceutical Corporation
Santen Launches Ikervis in Germany
TRACON Pharmaceuticals Announces IND Filing of DE-122 (TRC105) for the Treatment of Wet Age-Related Macular Degeneration by Santen Pharmaceutical
Intravitreal VEGF Inhibitor "EYLEA" Approved as a Treatment of Retinal Vein Occlusion(RVO)
Santen Launches COSOPT Mini Combination ophthalmic solution for the Treatment of Glaucoma and Ocular Hypertension
Notice of the appointment of Corporate Officers
Santen Reports Consolidated Performance for the Fiscal Year Ended March 31, 2015
Santen Announces Assignment of its Anti-Rheumatic Pharmaceuticals Business to Hyperion Pharma Co., Ltd.
Notice of Member of the Board and Corporate Auditors Nominations
Financial Results for the Fiscal Year Ended March 31, 2015
Santen Makes Contributions to Support the Recovery of Areas Affected by the Earthquake in Nepal
Santen Launches New Sante de U α, an OTC Eye Drop
Notice of Change in Significant Shareholder
Santen Announces Approval of Ikervis for EU Marketing Authorization
Revision of consolidated earnings forecasts for FY 2014
Santen Announces Proposed Dividends Change
Santen Announces Approval of Glaucoma and Ocular Hypertension Therapeutic,COSOPT Mini Ophthalmic Solution in Japan
Notice of the appointment of Corporate Officers
Santen to Co-sponsor "Green Light-Up"to Illuminate Landmark Facilities in Green in Japan during the World Glaucoma Week from March 8, 2015 to March 14, 2015
European Medicines Agency Accepts Santen's Marketing Application Filing for Intravitreal Sirolimus for the Treatment of Noninfectious Uveitis of the Posterior Segment
Santen Announces Stock Split and Amendment to the Articles of Incorporation
Santen Launches Sante Lutax®20+Vitamin& Mineral a Nutritional Supplement Containing Lutein
Santen receives a Positive CHMP Opinion for EU Marketing Authorization for Ikervis®
News Archive
Copyright © 2023 Santen Pharmaceutical Co., Ltd.
All Rights Reserved